|
Re: PERJETA + Herceptin + docetaxel nearly doubled pCR rates vs Herceptin-- NeoSphere
Yes, unlike the docetaxel component in the NeoSphere trial, the very potent maytansine toxin conjugated to the herceptin, boosted the pCR percentile in the ADAPT trial from 6.7 to 40+
|